Retrophin’s New Strategy Gets A Boost, And A Voucher, Thanks To Cholbam
This article was originally published in The Pink Sheet Daily
Executive Summary
The rare disease company, in the midst of a transition after losing its high-profile CEO last year, takes a step forward with the FDA approval of Cholbam for bile acid synthesis disorders. The company also gained a valuable priority review voucher, which it could sell.
You may also be interested in...
United Therapeutics Wins Unituxin Approval, Pediatric Priority Review Voucher – With NIH Support
The National Cancer Institute conducted the clinical trials of Unituxin for treatment of pediatric high-risk neuroblastoma and teamed with United for manufacturing and commercialization.
How Much Is A Priority Review Worth? $67.5 Million, Sanofi/Regeneron Say
Companies’ decision to purchase and redeem BioMarin’s priority review voucher for their PCSK9 inhibitor alirocumab sets the first public benchmark for a voucher’s value and shows the potential advantages to be gained for sponsors in a race to market.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.